Exciva Secures €51 Million Series B: Alzheimer's Agitation Therapy Advances to Phase 2
January 22, 2026, 3:38 am
Exciva closed a €51 million Series B funding round. This financing fuels Deraphan, its Alzheimer's agitation therapy, into crucial Phase 2 trials. EQT Life Sciences and Gimv spearheaded the investment. The global study addresses a pressing unmet medical need. Deraphan, a novel compound combination, demonstrated promising safety in Phase 1. This significant investment accelerates development for millions suffering from Alzheimer's behavioral symptoms. It offers new hope for patients and caregivers. The trial encompasses the European Union, United States, and Canada.
A significant financial injection boosts Alzheimer's drug development. Exciva, a biopharmaceutical innovator, secured €51 million. This Series B funding empowers the company. It will drive its lead candidate, Deraphan, into Phase 2 clinical trials. This marks a pivotal moment in the fight against neurodegenerative disease.
Agitation plagues millions with Alzheimer's disease. This pervasive symptom devastates patient quality of life. It places immense strain on caregivers. Healthcare systems face mounting costs. Up to ninety percent of severe Alzheimer's patients experience these neuropsychiatric symptoms. Current treatment options are often inadequate. Many carry significant side effects. Some offer inconsistent outcomes. A profound unmet medical need persists.
Exciva directly confronts this challenge. Its therapeutic candidate, Deraphan, targets agitation. Deraphan represents a novel approach. It combines two clinically validated compounds. One component is a new chemical entity. This unique formulation distinguishes it from existing treatments. Phase 1 trials demonstrated encouraging safety. Tolerability was also strong. This early success underpins its potential. Deraphan aims for a differentiated efficacy profile. It seeks improved safety compared to current standards.
The €51 million funding ensures Phase 2 trial commencement. This trial is critical. It evaluates Deraphan's therapeutic potential. The study will unfold across three major regions. These include the European Union, the United States, and Canada. Such a broad scope highlights the global ambition. It underscores the widespread problem Deraphan seeks to solve. Advancing to Phase 2 is a significant milestone. It validates Exciva's scientific foundation. It signals investor confidence in Deraphan's promise.
EQT Life Sciences co-led the funding round. Their LSP Dementia Fund was instrumental. Gimv also took a lead position. Both firms specialize in life sciences investments. Their involvement underscores the strategic importance of this venture. Additional participants include Fountain Healthcare Partners, LifeArc, Carma Fund, and Modi Ventures. Returning investors like Andera Partners and LBBW also contributed. This diverse investor base reflects broad confidence. It points to a shared vision for Alzheimer's care.
The investment extends beyond mere capital. EQT Life Sciences gains board representation. Philip Scheltens joins as a Director. Juliette Lee serves as a Board Observer. This brings deep scientific and strategic expertise. Such guidance is invaluable for clinical-stage companies. It strengthens Exciva's leadership. It enhances its strategic direction.
Alzheimer's research faces immense hurdles. Drug development is notoriously difficult. Many candidates fail in clinical trials. Yet, the urgency remains. An aging global population amplifies the need. Breakthroughs in neurodegenerative disease are rare. Every successful step generates immense hope. Exciva's progress offers a beacon. It targets a symptom with devastating impact.
Exciva was founded in 2016. Drs. Anton Bespalov, Hans Moebius, and Rao Vepachedu established the company. Their mission: address neuropsychiatric symptoms in brain disorders. Specifically, Alzheimer's disease dementia. Exciva leverages its discovery potential. It focuses on combining CNS-active compounds. This approach birthed Deraphan. Its Heidelberg, Germany base fosters innovation.
The successful completion of Phase 1 trials was crucial. It paved the way for this Series B. Patients desperately need better options. Current therapies often fall short. They can have severe side effects. Boxed warnings limit their use. Deraphan aims to overcome these limitations. It strives to deliver a safer, more effective treatment. This could transform patient care. It could significantly reduce caregiver burden.
The global Alzheimer's drug market is vast. It presents significant opportunities for effective therapies. Success for Deraphan would reshape this landscape. It would offer a new standard of care. This funding pushes Exciva closer to that reality. It empowers rigorous testing. It enables critical data collection.
The medical community watches closely. Positive Phase 2 results would be transformative. They would signal a major step forward. They would accelerate Deraphan towards further development. Ultimately, they offer potential relief for millions. This investment is not just financial. It represents a commitment to innovation. It symbolizes hope for a future with better Alzheimer's treatments. Exciva stands at the forefront of this crucial battle.
A significant financial injection boosts Alzheimer's drug development. Exciva, a biopharmaceutical innovator, secured €51 million. This Series B funding empowers the company. It will drive its lead candidate, Deraphan, into Phase 2 clinical trials. This marks a pivotal moment in the fight against neurodegenerative disease.
Agitation plagues millions with Alzheimer's disease. This pervasive symptom devastates patient quality of life. It places immense strain on caregivers. Healthcare systems face mounting costs. Up to ninety percent of severe Alzheimer's patients experience these neuropsychiatric symptoms. Current treatment options are often inadequate. Many carry significant side effects. Some offer inconsistent outcomes. A profound unmet medical need persists.
Exciva directly confronts this challenge. Its therapeutic candidate, Deraphan, targets agitation. Deraphan represents a novel approach. It combines two clinically validated compounds. One component is a new chemical entity. This unique formulation distinguishes it from existing treatments. Phase 1 trials demonstrated encouraging safety. Tolerability was also strong. This early success underpins its potential. Deraphan aims for a differentiated efficacy profile. It seeks improved safety compared to current standards.
The €51 million funding ensures Phase 2 trial commencement. This trial is critical. It evaluates Deraphan's therapeutic potential. The study will unfold across three major regions. These include the European Union, the United States, and Canada. Such a broad scope highlights the global ambition. It underscores the widespread problem Deraphan seeks to solve. Advancing to Phase 2 is a significant milestone. It validates Exciva's scientific foundation. It signals investor confidence in Deraphan's promise.
EQT Life Sciences co-led the funding round. Their LSP Dementia Fund was instrumental. Gimv also took a lead position. Both firms specialize in life sciences investments. Their involvement underscores the strategic importance of this venture. Additional participants include Fountain Healthcare Partners, LifeArc, Carma Fund, and Modi Ventures. Returning investors like Andera Partners and LBBW also contributed. This diverse investor base reflects broad confidence. It points to a shared vision for Alzheimer's care.
The investment extends beyond mere capital. EQT Life Sciences gains board representation. Philip Scheltens joins as a Director. Juliette Lee serves as a Board Observer. This brings deep scientific and strategic expertise. Such guidance is invaluable for clinical-stage companies. It strengthens Exciva's leadership. It enhances its strategic direction.
Alzheimer's research faces immense hurdles. Drug development is notoriously difficult. Many candidates fail in clinical trials. Yet, the urgency remains. An aging global population amplifies the need. Breakthroughs in neurodegenerative disease are rare. Every successful step generates immense hope. Exciva's progress offers a beacon. It targets a symptom with devastating impact.
Exciva was founded in 2016. Drs. Anton Bespalov, Hans Moebius, and Rao Vepachedu established the company. Their mission: address neuropsychiatric symptoms in brain disorders. Specifically, Alzheimer's disease dementia. Exciva leverages its discovery potential. It focuses on combining CNS-active compounds. This approach birthed Deraphan. Its Heidelberg, Germany base fosters innovation.
The successful completion of Phase 1 trials was crucial. It paved the way for this Series B. Patients desperately need better options. Current therapies often fall short. They can have severe side effects. Boxed warnings limit their use. Deraphan aims to overcome these limitations. It strives to deliver a safer, more effective treatment. This could transform patient care. It could significantly reduce caregiver burden.
The global Alzheimer's drug market is vast. It presents significant opportunities for effective therapies. Success for Deraphan would reshape this landscape. It would offer a new standard of care. This funding pushes Exciva closer to that reality. It empowers rigorous testing. It enables critical data collection.
The medical community watches closely. Positive Phase 2 results would be transformative. They would signal a major step forward. They would accelerate Deraphan towards further development. Ultimately, they offer potential relief for millions. This investment is not just financial. It represents a commitment to innovation. It symbolizes hope for a future with better Alzheimer's treatments. Exciva stands at the forefront of this crucial battle.